<DOC>
	<DOCNO>NCT02757079</DOCNO>
	<brief_summary>The purpose study evaluate efficacy sleep latency electronic sleep diary safety NPC-15 .</brief_summary>
	<brief_title>Study Efficacy Safety NPC-15 Sleep Disorders Children With Neurodevelopmental Disorders</brief_title>
	<detailed_description>This study multicenter open label trial . The trial three phase ; screen phase , treatment phase post-treatment phase . The screen phase comprises screen visit subject 's initial eligibility evaluate . During open label treatment phase , patient administer NPC-15 1 mg , 2 mg 4 mg basis doctor ' judgement .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Sleep Wake Disorders</mesh_term>
	<mesh_term>Parasomnias</mesh_term>
	<mesh_term>Neurodevelopmental Disorders</mesh_term>
	<mesh_term>Melatonin</mesh_term>
	<criteria>Female male patient age 6 15 year . Patients `` neurodevelopmental disorder '' diagnose use DSM5 . Patients average daily sleep latency persist 30 min condition continuous 3 month Patients outpatient , hospitalize patient . Signed informed consent obtain rearer ( ) /parent ( ) /guardian ( ) patient , sign IC inform assent obtain patient . Patients least severity either Conceptual area , Social area , Practical area intellectual disability judge `` severe '' use DSM5 . Patients take melatonin ( include supplement ) history . Patients take Ramelteon within 4 week clinical study start .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Melatonin</keyword>
	<keyword>NPC-15</keyword>
	<keyword>Sleep disorder</keyword>
	<keyword>Neurodevelopmental disorder</keyword>
	<keyword>Sleep latency</keyword>
	<keyword>DSM-5</keyword>
</DOC>